Literature DB >> 8630925

Prognostic value of ploidy and proliferation markers in renal cell carcinoma.

A Tannapfel1, H A Hahn, A Katalinic, R J Fietkau, R Kühn, C W Wittekind.   

Abstract

BACKGROUND: The prognosis for patients with renal cell carcinoma depends mainly on pathological stage and grade of the tumor at the time of surgery. Cellular proliferation may prove to be another measure for predicting biologic aggressiveness and, therefore, the prognosis.
METHODS: The authors compared four different methods to assess proliferation in a series of 87 curatively resected (R0) renal cell carcinomas: flow cytometry analysis (FCM), silver-stained nucleolar organizer regions (AgNOR), and immunohistochemical assessment of the MIB-1 (Ki-67) antigen, and proliferating cell nuclear antigen (PCNA). The results obtained were compared with pathologic stage (according to the International Union Against Cancer [UICC]) and grade with disease-related survival rate; finally, we assessed whether the methods led to similar results.
RESULTS: In each carcinoma examined, we could demonstrate MIB-1, PCNA, and AgNOR dots in varied proportions. Statistical correlations were seen between the tumor grade, the rate of nuclear positivity for MIB-1 and PCNA, and the number of AgNOR dots. Additionally, the MIB-1 index was significantly higher in more advanced tumor stages. A good correlation between MIB-1 and AgNOR as well as for PCNA was found. In univariate survival analysis, tumor stage and grade, MIB-1 and PCNA index, and mean AgNOR number were related significantly to patient survival. On multivariate Cox disease-related survival analysis, stage of disease and MIB-1 were significant independent prognostic factors. Flow cytometry was not related to prognosis nor to other examined parameters.
CONCLUSIONS: These results indicated that MIB-1 immunostaining is an additional prognostic parameter for patient outcome. MIB-1 and PCNA immunostaining, as well as AgNOR, demonstrated good correlations among themselves. We failed to establish flow cytometry as a method to predict proliferative capacity or prognosis in renal cell carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630925     DOI: 10.1002/(SICI)1097-0142(19960101)77:1<164::AID-CNCR27>3.0.CO;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Prognostic value of MIB-1 index and DNA ploidy in resectable ampulla of Vater carcinoma.

Authors:  Y M Shyr; C H Su; L H Wu; A F Li; J H Chiu; C W Wu; W Y Lui
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

2.  Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver.

Authors:  A Tannapfel; L Weinans; F Geissler; A Schütz; A Katalinic; F Köckerling; J Hauss; C Wittekind
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

3.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

Authors:  R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

Review 4.  Classical pathology versus molecular pathology in renal cell carcinoma.

Authors:  Peggy Soung Sullivan; JianYu Rao; Liang Cheng; Richard J Cote
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

5.  Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.

Authors:  Thilo Bluethner; Manuel Niederhagen; Karel Caca; Frederik Serr; Helmut Witzigmann; Christian Moebius; Joachim Mossner; Marcus Wiedmann
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

6.  Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.

Authors:  Martin Haefner; Thilo Bluethner; Manuel Niederhagen; Christian Moebius; Christian Wittekind; Joachim Mossner; Karel Caca; Marcus Wiedmann
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

7.  [Proliferation and apoptosis before and after preoperative simultaneous radiochemotherapy of rectal carcinomas].

Authors:  A Tannapfel; S Nüsslein; A Katalinic; F Köckerling; C Wittekind; R Fietkau
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

8.  Multiple simultaneous gastric carcinomas.

Authors:  C Wittekind; M Klimpfinger; P Hermanek; A Tannapfel
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma.

Authors:  F Donskov; N Marcussen; M Hokland; R Fisker; H H T Madsen; H von der Maase
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

Review 10.  Novel concepts in the staging of renal cell carcinoma.

Authors:  Dan Leibovici; Arie Lindner; Avishay Sella; Amnon Zisman
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.